AlphAIAlphAI — Financial news for AI agents
globenewswire.comSEP 302 min read$CADL

Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

Candel Therapeutics (CADL) presented data at ASTRO 2026 showing aglatimagene besadenovec significantly increased immune response in prostate cancer patients over two years. The phase 3 trial showed 80% of aglatimagene patients had negative biopsies vs. 63% of controls. The company plans to submit a BLA based on these results.

Original reporting
globenewswire.com
Published Sep 30, 2026, 12:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 12:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CADL
Bullish
high confidence
Mentioned
$CADL
Relevance
8/10
AlphAI data visualization · based on globenewswire.com
Decision brief

The 30-second read

$CADLBullishMed
01

Why it matters

The new biomarker data provide mechanistic validation of aglatimagene's immune‑remodeling claim, supporting the previously reported disease‑free survival benefit and may accelerate BLA filing.

02

Market read

First public release of supportive phase‑3 biomarker data; likely to generate short‑term upside for CADL and influence peer biotech valuations.

03

What to watch

Regulatory timeline for BLA submission and potential competition from other viral immunotherapies.

Relevance 8/10Novelty 8/10Timing: post‑presentation today

Background

Candel Therapeutics (NASDAQ: CADL) is a clinical‑stage biotech developing aglatimagene, an off‑the‑shelf adenoviral immunotherapy. The company has Fast Track designations for prostate, NSCLC, and pancreatic indications.

Company-level read

Ticker impact

$CADLBullishHigh confidence
Context

Candel Therapeutics presented new phase‑3 biomarker data showing sustained immune remodeling two years after aglatimagene treatment, a first‑time disclosure.

Expected impact

upward pressure as market prices in the favorable immune‑remodeling results

Evidence & confidence

First public release of supportive phase‑3 data; FDA Fast Track already granted, so new efficacy evidence is material and likely to improve valuation.

Market effects

Sector

Strengthens the adenovirus‑based immunotherapy niche and may boost peer biotech sentiment.

Regional

US biotech sector could see modest gains as investors reassess similar candidates.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

Data are biomarker‑focused and not direct survival outcomes; market may already price optimism.

Key entities

  • company
    Candel Therapeutics

    Clinical‑stage biotech developing aglatimagene immunotherapy.

  • product
    Aglatimagene besadenovec

    Investigational adenovirus‑based immunotherapy for localized prostate cancer.

Read at source← All news

Related articles

OCT 22
$CADLMedAI 8/10

Jefferies initiates Candel Therapeutics stock with buy rating on prostate cancer data

Jefferies initiated Candel Therapeutics (NASDAQ:CADL) with a buy rating and $25 price target, citing positive Phase III prostate cancer data. The stock trades at $8.37, with analyst targets ranging from $15 to $29. The company has a strong financial position and plans a 2026 biologics license application. Recent data showed a hazard ratio of 0.70 and 80.4% negative biopsy rate. Other analysts also reiterated buy ratings and raised price targets.

investing.com2 min
OCT 2
$CADLHighAI 8/10

H.C. Wainwright reiterates Candel Therapeutics stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $23 price target for Candel Therapeutics (CADL) after positive Phase 2a trial results for non-small cell lung cancer. The stock is up 88% in a year, with analysts' targets ranging from $15 to $29. The trial showed a median overall survival of 24.5 months, higher than historical benchmarks. Several analysts have recently upgraded or initiated coverage with Buy ratings and price targets between $15 and $23.

investing.com2 min
OCT 1
$CADLMedAI 9/10

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI

Candel Therapeutics (CADL) reported phase 2a trial results showing median overall survival of 24.5 months in advanced NSCLC patients with inadequate response to immune checkpoint inhibitors. The trial involved 46 patients treated with aglatimagene besadenovec plus valacyclovir. Results were published in the Journal for ImmunoTherapy of Cancer. The company is advancing a phase 3 trial (AURORA) for this treatment.

globenewswire.com3 min
SEP 30
$CADLMedAI 8/10

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

Candel Therapeutics (CADL) reported positive data from its phase 2 PrTK05 trial, showing durable immune activation in intermediate-risk prostate cancer patients. Aglatimagene treatment reduced recurrence risk by 41% vs. placebo. The company plans to submit a BLA in Q4 2026. Data will be presented at future scientific meetings.

globenewswire.com3 min